At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 2 enrolled
Drug / intervention
MV-NISdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of Oncolytic Virotherapy by Systemic Administration of Edmonston Strain of Measles Virus, Genetically Engineered to Express NIS, With Cyclophosphamide, in Patients With Recurrent of Refractory Multiple Myeloma
In Brief
A Phase 2 clinical trial evaluating MV-NIS for Multiple Myeloma. Completed, enrolled 2 participants across 1 site.
Detailed Summary
The purpose of this study is to determine the clinical efficacy of MV-NIS (measles virus-sodium iodide symporter) therapy for people with relapsed/refractory myeloma when given with cyclophosphamide
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartMar 2015
Primary CompletionAug 2019
TodayJul 2026
First PostedJul 17, 2014
Enrollment StartMar 1, 2015
Primary CompletionAug 20, 2019
TodayJul 2, 2026
Enrollment to primary: 4.5 yearsPosted 12.0 years ago
Interventions
MV-NISdrug
one dose in conjunction with a 4 day course intravenously